CTI BioPharma Corp. CTIC Financial and Strategic SWOT Analysis Review Prices from USD $125

02:42 EST 23 Nov 2016 | BioPortfolio Reports

CTI BioPharma Corp. CTIC Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


CTI BioPharma Corp. CTI BioPharma, formerly Cell Therapeutics, Inc., is a biopharmaceutical company which acquires, develops, and commercializes targeted therapies for the treatment of a range of bloodrelated cancers. The company's lead product, Pixuvri pixantrone dimaleate is a azaanthracenedione that is used for the treatment of adult patients with multiply relapsed or refractory aggressive Bcell nonHodgkin lymphoma NHL. Its pipeline portfolio encompasses indications for the treatment of multiply relapsed aggressive Bcell NHL, myelofibrosis for all platelet counts, ovarian cancer, myelodysplastic syndromes, and relapsed acute myeloid leukemia. The company has subsidiaries in Europe and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.

CTI BioPharma Corp. Key Recent Developments

May 10, 2016: CTI BioPharma Reports First Quarter 2016 Financial Results
Feb 16, 2016: CTI BioPharma Reports Fourth Quarter And Full Year 2015 Financial Results
Jan 13, 2016: CTI BioPharma Appoints Matthew Perry To Board Of Directors
Jan 11, 2016: CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For Transformational 2016
Nov 05, 2015: CTI BioPharma Reports Third Quarter 2015 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: CTI BioPharma Corp. CTIC Financial and Strategic SWOT Analysis Review Prices from USD $125


More From BioPortfolio on "CTI BioPharma Corp. CTIC Financial and Strategic SWOT Analysis Review Prices from USD $125"

Quick Search

Relevant Topic

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...